Deuterated S-Lenalidomide Solid Forms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of novel solid forms of deuterated lenalidomide, specifically the S-enantiomer, is necessary to enhance its metabolic properties such as absorption, distribution, metabolism, and excretion (ADME) without adversely affecting its pharmacological properties, which is crucial for improving its therapeutic efficacy in treating inflammatory, infectious, and malignant diseases.
Innovation Solution
The patent describes four distinct solid forms of deuterated S-lenalidomide, including Forms 1, 2, 3, and an amorphous form, characterized by their crystalline and amorphous structures, which are further differentiated by their hydration states and stability, utilizing advanced analytical techniques like PXRD, Raman spectroscopy, and DSC to ensure purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deuterated lenalidomide is developed to improve metabolic properties (ADME), then absorption, distribution, metabolism and excretion are enhanced, but the complexity of manufacturing and characterization increases
Solution Approach 1:
The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms at specific positions in the lenalidomide molecule (positions 3, 4, 4a, 5, 7, 8, or 12). This isotopic substitution modifies the metabolic properties and ADME profile of the compound while maintaining its pharmacological activity, thereby improving reliability without fundamentally changing the manufacturing process complexity
Solution Approach 2:
The invention applies local quality by selectively deuterating specific positions on the lenalidomide molecule rather than the entire molecule. This targeted approach allows optimization of metabolic properties at specific sites while simplifying the overall manufacturing process compared to complete deuteration, as only particular hydrogen atoms need to be replaced
2Reliability
If multiple solid forms are developed to improve solubility and stability, then therapeutic effectiveness is enhanced, but the complexity of characterization and quality control increases
Solution Approach 1:
The patent applies phase transitions by developing multiple solid forms (crystalline polymorphs, amorphous forms, solvates, and hydrates) of deuterated lenalidomide. Each solid form represents a different phase or structural arrangement of the same molecular compound, offering improved solubility and stability profiles while providing distinct characterization patterns for quality control
Solution Approach 2:
The invention applies universality by creating a comprehensive suite of solid forms that serve multiple functions: crystalline forms provide stability, amorphous forms enhance solubility, solvates offer intermediate properties, and hydrates provide additional stability options. This multi-functional approach allows selection of the optimal solid form for each specific therapeutic application
3Reliability
If deuterium enrichment is increased to improve metabolic properties, then ADME profile is optimized, but the cost and complexity of synthesis increases
Solution Approach 1:
The patent applies parameter changes by controlling the degree of deuterium enrichment at specific molecular positions. Rather than requiring complete deuteration (100% enrichment), the invention achieves optimized ADME profiles with partial enrichment (e.g., 50-95% deuterium at specific positions), thereby improving metabolic properties while reducing synthesis complexity and cost
Solution Approach 2:
The invention applies partial action by deuterating only specific positions on the lenalidomide molecule rather than all hydrogen atoms. This selective partial deuteration achieves the necessary metabolic optimization while significantly simplifying the synthesis process compared to complete molecule deuteration, making the manufacturing more economically viable
Data Source
AI summary
The invention in one embodiment is directed to solid forms of {S-3-(4-Amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}, including an anhydrous crystalline form, two hydrates, and an amorphous form. The invention in one embodiment is directed to methods of preparation of the solid forms.